초록
<P><B>Abstract</B></P> <P>The probiotic bacterium, <I>Lactobacillus reuteri,</I> possesses a unique pathway for metabolizing glycerol into 3-hydroxypropionic acid (3-HP) and 1,3-propanediol (1,3-PD), which are two important platform chemicals. In this work, a potent <I>L. reuteri</I> strain, designated as FXZ014, was isolated and identified from healthy human feces for co-biosynthesis of 3-HP and 1,3-PD during whole cell biotransformation of glycerol. Initially, biotransformation conditions were optimized for this new strain using single factor optimization and response surface methodology (RSM). Under the optimum batch conditions, FXZ014 produced 8.74 ± 0.24 g/L of 3-HP and 9.94 ± 0.36 g/L of 1,3-PD with a corresponding net yield of 0.67 mol/mol. Finally, efficiency of the isolated strain in the co-production of these two metabolites was compared with the same of a reference strain, namely <I>L. reuteri</I> CICC 6118. Compared to the reference strain, the amounts of 3-HP and 1,3-PD produced by the isolated strain were significantly higher that corresponded to 38.4% and 21.14%, respectively. Therefore, FXZ014 could be a promising natural strain for co-biosynthesis of 3-HP and 1,3-PD from glycerol.</P> <P><B>Highlights</B></P> <P> <UL> <LI> <I>Lactobacillus reuteri</I> FXZ014 was newly isolated for glycerol biotransformation. </LI> <LI> Biotransformation conditions were optimized for the co-production of 3-HP and 1,3-PD. </LI> <LI> FXZ014 produced 8.74 g/L of 3-HP and 9.94 g/L of 1,3-PD with 0.67 mol/mol net yield. </LI> <LI> Results were compared between FXZ014 and a reference strain (<I>L. reuteri</I> CICC 6118). </LI> <LI> The net yield of 3-HP plus 1,3-PD was 28.5% higher for FXZ014 than for CICC 6118. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>